← Back to Clinical Trials
Recruiting NCT04368039

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

Trial Parameters

Condition Psychosis
Sponsor Nicholas Breitborde
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 15 Years
Max Age 35 Years
Start Date 2019-12-04
Completion 2026-12-07
Interventions
Normobaric OxygenPlacebo

Brief Summary

Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.

Eligibility Criteria

* Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5. * Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory . * No evidence of a pre-existing intellectual disability defined as a premorbid IQ \>70 as estimated using the Reading subtest of the Wide Range Achievement Test-4. * Ages 15-35 * Non-smoker for past six months * Absence of suicidal ideation or behavior over the past month as assessed by the Columbia Suicide Severity Rating Scale * The American Association for Respiratory Care notes that "no absolute contraindications to oxygen therapy exist when indications \[for oxygen therapy\] are present."

Related Trials